Controversial FDA Approval Of Alzheimer's Drug Aducanumab Sets Stage For Possible Medicare Coverage Battle
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies | Biogen
The Science of Aging: Summer 2020 – The Science of Aging
Aduhelm (aducanumab) Q+A - Penn Memory Center
With Spotlight on Alzheimer's Disease and Biogen, Competitors' Stocks Soar | BioSpace
Medicare Finalizes Limits on Aducanumab Coverage | MedPage Today
Biogen releases long-term Aduhelm data
Aducanumab: New Medication FDA Approved for Alzheimer's Disease – Psychiatry Education Forum
Biogen's Alzheimer's drug approved by FDA, first new therapy in nearly two decades
Biogen's Aducanumab: A Look at the Drug's History and Recent Updates | BioSpace
FDA changes prescribing instructions to limit use of contentious Alzheimer's drug amid public backlash | KTLA
Congressional Probe of Alzheimer's Drug Approval Finds Fault With FDA Actions | MedPage Today
Aducanumab: will Biogen's Aduhelm recover from its rocky start? - Pharmaceutical Technology
Biogen's Alzheimer's Drug Gets FDA Approval, Mixed Reviews | The Scientist Magazine®
FDA approves Aduhelm, first new drug for Alzheimer's in 20 years, despite questions - CBS News
Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer's Disease | Biogen
FDA's Approval of Biogen's New Alzheimer's Drug Has Huge Cost Implications for Medicare and Beneficiaries | KFF
U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day" for patients | Reuters
FDA Approval of a New Alzheimer's Drug Comes With Controversy | Smart News| Smithsonian Magazine
Biogen stuns with planned US FDA filing for previously scrapped Alzheimer's drug | S&P Global Market Intelligence
EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD™ 2023 ANNUAL MEETING
Biogen gives up seeking European approval for aducanumab - Drug Discovery and Development
June 7, 2021: A Historic Day | The Long and Winding Road...
Biogen is ready to roll on lecanemab production, CFO says
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease | Nature
EMA gives thumbs down to Biogen's Alzheimer's drug aducanumab - Drug Discovery and Development
Aduhelm safety: the data gap on aducanumab's brain swelling side effect
